Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Becton Dickinson and Co (NYSE:BDX)

179.50
Delayed Data
As of Sep 23
 -2.05 / -1.13%
Today’s Change
128.87
Today|||52-Week Range
181.76
+16.49%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$38.2B

Company Description

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in a wide range of healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Contact Information

Becton, Dickinson & Co.
1 Becton Drive
Franklin Lakes New Jersey 07417-1880
P:(201) 847-6800
Investor Relations:
(201) 847-5378

Employees

Shareholders

Mutual fund holders46.60%
Other institutional39.10%
Individual stakeholders0.82%

Top Executives

Vincent A. ForlenzaChairman, President & Chief Executive Officer
Christopher R. ReidyEVP, Chief Financial & Administrative Officer
Ellen R. StrahlmanChief Medical Officer, EVP-Research & Development
Patti E. RussellSenior VP, Chief Ethics & Compliance Officer
Gary M. CohenPresident-Global Health & Executive VP